JP2024533122A - フラビウイルス治療用の２’－クロロ－２’－フルオロ－ｎ２－アミノ－ｎ６－メチルアミノプリンヌクレオチド - Google Patents

フラビウイルス治療用の２’－クロロ－２’－フルオロ－ｎ２－アミノ－ｎ６－メチルアミノプリンヌクレオチド Download PDF

Info

Publication number
JP2024533122A
JP2024533122A JP2024513754A JP2024513754A JP2024533122A JP 2024533122 A JP2024533122 A JP 2024533122A JP 2024513754 A JP2024513754 A JP 2024513754A JP 2024513754 A JP2024513754 A JP 2024513754A JP 2024533122 A JP2024533122 A JP 2024533122A
Authority
JP
Japan
Prior art keywords
compound
use according
virus
administered
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533122A5 (https=
Inventor
ジャン－ピエール ソマドッシ
アデル ムーサ
Original Assignee
アテア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アテア ファーマシューティカルズ， インコーポレイテッド filed Critical アテア ファーマシューティカルズ， インコーポレイテッド
Priority claimed from PCT/US2022/042545 external-priority patent/WO2023034617A1/en
Publication of JP2024533122A publication Critical patent/JP2024533122A/ja
Publication of JP2024533122A5 publication Critical patent/JP2024533122A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024513754A 2021-09-03 2022-09-02 フラビウイルス治療用の２’－クロロ－２’－フルオロ－ｎ２－アミノ－ｎ６－メチルアミノプリンヌクレオチド Pending JP2024533122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240578P 2021-09-03 2021-09-03
US63/240,578 2021-09-03
PCT/US2022/042545 WO2023034617A1 (en) 2021-09-03 2022-09-02 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment

Publications (2)

Publication Number Publication Date
JP2024533122A true JP2024533122A (ja) 2024-09-12
JP2024533122A5 JP2024533122A5 (https=) 2025-09-09

Family

ID=85380756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513754A Pending JP2024533122A (ja) 2021-09-03 2022-09-02 フラビウイルス治療用の２’－クロロ－２’－フルオロ－ｎ２－アミノ－ｎ６－メチルアミノプリンヌクレオチド

Country Status (7)

Country Link
US (1) US20240226131A1 (https=)
EP (1) EP4395787A4 (https=)
JP (1) JP2024533122A (https=)
KR (1) KR20240052801A (https=)
CN (1) CN118234499A (https=)
AU (1) AU2022339679A1 (https=)
CA (1) CA3174107A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018048937A1 (en) * 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
WO2021173713A1 (en) * 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19

Also Published As

Publication number Publication date
CA3174107A1 (en) 2023-03-03
CN118234499A (zh) 2024-06-21
EP4395787A1 (en) 2024-07-10
EP4395787A4 (en) 2025-07-23
US20240226131A1 (en) 2024-07-11
AU2022339679A1 (en) 2024-03-07
KR20240052801A (ko) 2024-04-23

Similar Documents

Publication Publication Date Title
JP7124024B2 (ja) Ｒｎａウイルス治療に対する２’－置換－ｎ６－置換プリンヌクレオチド
JP7532440B2 (ja) ＨＣＶ治療に対するβ－Ｄ－２’－デオキシ－２’－α－フルオロ－２’－β－Ｃ－置換－２－修飾－Ｎ６－置換プリンヌクレオチド
US11266666B2 (en) Methods for treating Filoviridae virus infections
JP7559223B2 (ja) リン脂質化合物及びその使用
JP2024533122A (ja) フラビウイルス治療用の２’－クロロ－２’－フルオロ－ｎ２－アミノ－ｎ６－メチルアミノプリンヌクレオチド
WO2023034617A1 (en) 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment
RU2776918C2 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
HK40008711B (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250901